BridgeBio Pharma (BBIO) Depreciation & Amortization (CF) (2018 - 2026)

BridgeBio Pharma (BBIO) has 9 years of Depreciation & Amortization (CF) data on file, last reported at $1.2 million in Q1 2026.

• For the quarter ending Q1 2026, Depreciation & Amortization (CF) fell 7.63% year-over-year to $1.2 million; the trailing twelve-month figure through Mar 2026 stood at $5.3 million (down 7.41% YoY), and the FY2025 full-year result was $5.4 million, down 10.55% from the prior year.
• Depreciation & Amortization (CF) retreated to $1.2 million in Q1 2026, from $1.4 million in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $1.9 million in Q1 2022 to a low of $1.2 million in Q1 2026.
• A 5-year average of $1.5 million and a median of $1.6 million in 2022 frame the typical range for Depreciation & Amortization (CF).
• Peak annual rise in Depreciation & Amortization (CF) reached 520.75% in 2022, while the deepest fall reached 54.62% in 2022.
• Tracing BBIO's Depreciation & Amortization (CF) over 5 years: stood at $1.7 million in 2022, then retreated by 4.52% to $1.6 million in 2023, then fell by 13.75% to $1.4 million in 2024, then advanced by 4.97% to $1.4 million in 2025, then fell by 17.35% to $1.2 million in 2026.
• Business Quant data shows BBIO's Depreciation & Amortization (CF) at $1.2 million in Q1 2026, $1.4 million in Q4 2025, and $1.4 million in Q3 2025.